Concepts (48)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pseudopregnancy | 1 | 2005 | 1 | 0.230 |
Why?
|
| Dizocilpine Maleate | 1 | 2005 | 11 | 0.230 |
Why?
|
| Chlordiazepoxide | 1 | 2005 | 4 | 0.230 |
Why?
|
| Maze Learning | 1 | 2005 | 51 | 0.220 |
Why?
|
| Progesterone | 1 | 2005 | 165 | 0.210 |
Why?
|
| Huntington Disease | 2 | 2002 | 159 | 0.080 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2002 | 22 | 0.060 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2002 | 24 | 0.060 |
Why?
|
| Gonadotropins, Equine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Rats, Long-Evans | 1 | 2005 | 22 | 0.060 |
Why?
|
| Pregnanolone | 1 | 2005 | 12 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2005 | 38 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 31 | 0.060 |
Why?
|
| Exploratory Behavior | 1 | 2005 | 36 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2005 | 103 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 200 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 850 | 0.050 |
Why?
|
| Genes, Immediate-Early | 1 | 2002 | 8 | 0.050 |
Why?
|
| Neostriatum | 1 | 2002 | 26 | 0.050 |
Why?
|
| Motor Activity | 1 | 2005 | 347 | 0.050 |
Why?
|
| Rats | 1 | 2005 | 1996 | 0.040 |
Why?
|
| Peptides | 1 | 2002 | 588 | 0.040 |
Why?
|
| Proteins | 1 | 2002 | 762 | 0.030 |
Why?
|
| Neurons | 1 | 2002 | 940 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 1633 | 0.030 |
Why?
|
| Brain | 1 | 2002 | 1594 | 0.030 |
Why?
|
| Animals | 3 | 2005 | 21289 | 0.020 |
Why?
|
| Huntingtin Protein | 2 | 2002 | 147 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2002 | 430 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2002 | 1285 | 0.020 |
Why?
|
| Female | 3 | 2005 | 33740 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2002 | 793 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2002 | 1572 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 2271 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Dopamine Agonists | 1 | 2002 | 22 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 2002 | 15 | 0.010 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2002 | 17 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 152 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 215 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 197 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 298 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 543 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1984 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 792 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 11079 | 0.010 |
Why?
|
| Male | 2 | 2002 | 30798 | 0.010 |
Why?
|
| Humans | 1 | 2002 | 64745 | 0.000 |
Why?
|